Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$110 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-6.9
Face value
--
Shares outstanding
12,236,800
CFO
$-345.68 Mln
EBITDA
$-449.95 Mln
Net Profit
$-445.93 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Corbus Pharmaceuticals Holding (CRBP)
| -24.3 | 38.4 | 29.2 | -82.3 | 0.8 | -46.7 | -21.0 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Corbus Pharmaceuticals Holding (CRBP)
| 94.3 | 82.2 | -82.0 | -50.7 | -77.1 | -6.5 | -17.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Corbus Pharmaceuticals Holding (CRBP)
|
8.9 | 109.8 | 0.0 | -50.3 | -- | -36.2 | -- | 0.9 |
| 51.0 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.1 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.6 | 7,421.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 54.0 | 10,499.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 41.6 | 11,298.3 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.1 | 5.5 | |
| 302.7 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 26.6 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 125.2 | 12,288.6 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 | |
| 284.4 | 12,470.6 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 12.9 | 2.2 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic... payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Address: 500 River Ridge Drive, Norwood, MA, United States, 02062 Read more
CEO & Director
Dr. Yuval Cohen Ph.D.
CEO & Director
Dr. Yuval Cohen Ph.D.
Headquarters
Norwood, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Corbus Pharmaceuticals Holding (CRBP) stood at $ 152 Mln as on 31-Mar-25
The share price of Corbus Pharmaceuticals Holding (CRBP) is $8.93 (NASDAQ) as of 13-Jun-2025 13:36 EDT. Corbus Pharmaceuticals Holding (CRBP) has given a return of 0.76% in the last 3 years.
Corbus Pharmaceuticals Holding (CRBP) has a market capitalisation of $ 110 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Corbus Pharmaceuticals Holding (CRBP) is 0.86 times as on 12-Jun-2025, a 68% discount to its peers’ median range of 2.65 times.
Since, TTM earnings of Corbus Pharmaceuticals Holding (CRBP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Corbus Pharmaceuticals Holding (CRBP) and enter the required number of quantities and click on buy to purchase the shares of Corbus Pharmaceuticals Holding (CRBP).
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Address: 500 River Ridge Drive, Norwood, MA, United States, 02062
The CEO & director of Dr. Yuval Cohen Ph.D.. is Corbus Pharmaceuticals Holding (CRBP), and CFO & Sr. VP is Dr. Yuval Cohen Ph.D..
There is no promoter pledging in Corbus Pharmaceuticals Holding (CRBP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Corbus Pharmaceuticals Holding (CRBP) | Ratios |
|---|---|
|
Return on equity(%)
|
-36.23
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Corbus Pharmaceuticals Holding (CRBP) was $0 Mln.
$-0.24
(
